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HAS BEHAVIORAL SCIENCE TUMBLED THROUGH THE BIOLOGICAL
LOOKING GLASS? WILL BRIEF, EVIDENCE-BASED TRAINING
RETURN IT FROM THE RABBIT HOLE?
Donna M. Midkiff and W. Joseph Wyatt1
Marshall University

ABSTRACT: Time constraints and professional demands leave practicing professionals
unlikely to enroll in extended training such as a semester-long graduate course. Thus, the
three-hour continuing education format has become a standard for those in practice. One
may ask what sorts of training strategies optimize that format. To explore that, a threehour training program for seventy-six practicing mental health professionals, most of
whom self-identified as psychologists, was devised. It made use of primarily antecedent
techniques that have been shown to bring about changed perceptions on a number of
topics. Content focused on two areas of importance to behavior analysts, the culture’s
increasing acceptance of the biological causation model of disorders such as attentiondeficit hyperactivity disorder (ADHD), unipolar depression, anxiety disorders, and
schizophrenia, and the field’s increasing reliance on medications, often to the exclusion
of behavioral methods. Pre-post assessment showed that participants had changed their
thinking regarding the two content areas. The authors caution that participants’ changed
opinions may serve as setting events to changes in practice, but those changes are verbal.
One must not assume changes in practice techniques will automatically occur.
KEYWORDS: brief training, continuing education, biological causation, biological
psychiatry, pharmaceutical industry

The shaping of opinions is of interest to those in both the behavioral sciences
and clinical practice. What factors are involved when a professional’s opinion is
changed regarding an important issue within the field? This study was an effort to
explore that question by looking at professionals’ opinions regarding the causes of
disorders and the factors that may change their thinking, within the context of
what is arguably the most common format for ongoing training, a three-hour
continuing education program. A timely topic was selected as content—the
1
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mental health field’s increasing turn to biological explanations, and the cooccurring rise of psychotropic medications as the treatment of choice. Some
background on those issues is helpful.
A Changed Cultural Worldview
Clearly, a number of disorders such as dementias, Down’s syndrome, and
disorders attributable to brain tumors, intracranial infection, and toxins are
biologically caused. In contrast, the causes of other disorders, such as the majority
of cases of depression, anxiety, attention-deficit hyperactivity disorder (ADHD)
and schizophrenia often are unknown and likely vary from patient to patient.
Adding to the difficulty in teasing out causes of the latter disorders is that some of
them may be said to be the result of learning histories that act upon biological
predispositions.
It has been suggested that matters such as guild protectionism and economics
have driven a preference for biological explanations of behavioral disorders in
recent decades, and that both the professional and public communities are willing
to endorse the biological model at levels of confidence that go well beyond the
data (Terry & Kohlenberg, 2006; Valenstein, 1998; Winston, 2006; Wong, 2006a;
Wong, 2006b; Wong, 2007; Wyatt, 2003; Wyatt, 2006; Wyatt & Midkiff, 2006a;
Wyatt & Midkiff, 2006b; Wyatt & Midkiff, 2007). Many years ago, Skinner had
observed the beginnings of this phenomenon when he coined the term
“conceptual nervous system,” to point out that human biology had become a
convenient “dumping ground” where the cause of any unexplained abnormal
behavior is hypothesized to lie (Skinner, 1974, pp. 48-49).
The biological worldview of common disorders such as depression and
anxiety has strengthened in recent years, despite opinions that there exists
relatively modest evidence to directly support it, at least for many cases of such
disorders (Antonuccio, Danton, DeNelsky, Greenberg & Gordon, 1999; Wyatt,
2003; Wyatt & Midkiff, 2006). Additionally, behaviors perhaps best thought of as
natural reactions are now, at times, erroneously conceptualized as biological
disorders (Horowitz & Wakefield, 2007). Moreover, it is clear that learning theory
provides a plausible basis for the etiology and maintenance of many problems in
functioning such as anxiety disorders and most child conduct problems (Mineka
& Zinbarg, 2006) as well as for many cases of depression (Seligman, 1975;
Abramson, Metalsky & Alloy, 1989) and other disorders. A more complete
discussion of the debate may be found in special issues of Behavior and Social
Issues (Special Issue: Mental Illness, Mental Health, and Cultural Analytic
Science, 2006; Special Section: Behavior Analysis, Biological Determinism, and
Biological Psychiatry, 2007).
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Increasing medicalization of behavioral disorders may impede implementation of non-drug treatment. A new patient may come to therapy already
convinced by advertising or the family doctor that his problems are genetic or
chemical in nature, regardless of whether there is evidence to support that notion.
The culture’s resulting preference for medications over other therapies is
illustrated by recent studies. When parents were given a prescription for a drug
and then told to also enroll their ADHD children in behavioral intervention
programs, only twenty-five percent did so. In contrast, when parents were told by
their doctors to first try behavioral interventions, ninety-five percent did so
(Pelham, 2009). A 2001 to 2003 study of over 80,000 adults and 5,000 children
by managed care tracker Medco Health Solutions found that in the three months
following initial prescription of an antidepressant, more than three quarters of the
adults and over half of the children had not had a mental health visit (Stettin, Yao,
Verbrugge, & Aubert, 2006).
In this atmosphere it is probable that, for many mental health professionals,
there exist gaps between their acceptance of biological causation and the state of
the research. A brief, data-based training program might bring about changes in
their thinking. Because active professionals typically receive training in half-day
or full-day continuing education programs, it is helpful to work within such time
frames. However, research-based training of well-functioning individuals has
typically targeted university students, parents of children with behavioral
problems and caregivers for those with disabilities, rather than mental health
professionals. Evidently little or no research has been conducted regarding worldview change among practicing mental health professionals.
Such professionals should be knowledgeable regarding a number of thorny
issues. These include psychiatry’s shift to biological formulations of disorders,
interpretation conundrums within family/genetic and brain function studies,
disputed drug study methodology and questionable pharmaceutical industry
marketing tactics. (See the special issues that are referenced above.)
Training approaches
A great deal has been written about educational practices that best bring
about changes in beliefs, attitudes and opinions (e.g., Allen & Preiss, 1998;
Cialdini, 2001; Dillard & Pfau, 2002; Perloff, 1993). The great majority of such
studies have targeted individuals other than the mental health practitioners. For
the most part, the literature has focused upon changing beliefs concerning
political matters, consumer products and guilt or innocence of defendants in
criminal and civil cases. There exists some behavioral literature on training wellfunctioning adults. However, it often involves parent training or training
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caregivers for the disabled, or it has focused on changing the classroom
performance of university students over the course of a full academic semester
(e.g., Ryan & Hemmes, 2005; Saville, Zinn, Neef, Van Norman, & Ferreri, 2006).
An EBSCO host search revealed no results for “attitude change” or “opinion
change” when these terms were combined with any of the following: mental
health, schizophrenia, depression, anxiety or ADHD. Additional search of the
literature uncovered no other relevant sources.
Despite the lack of empirical evidence relative to the mental health field and
attitude change, some fairly consistent findings have emerged regarding a number
of variables that are thought to be influential in changing beliefs of listeners. For
example, physical attractiveness of the speaker tends to exert a positive influence
on message acceptance (e.g., Cialdini, 2001; Haughtvedt, 1997; Perloff, 1993).
Similarly, perceived prestige of the speaker tends to enhance attitude change
(Aronson & Golden, 1962; Berlo, Lemest, & Martin, 1969; Eagly, Wood, &
Chaiken, 1978; Haughtvedt, 1997).
A speaker’s verbal presentation style has impact upon the listener’s adoption
of the speaker’s position. That is, a speaker’s verbal speed, intensity, choice of
words and the like will influence the resulting level of agreement with the
speaker’s position (Perloff, 1993). A review of the influence of verbal style
revealed several factors that any speaker would do well to practice. An extensive
vocabulary is beneficial; use of declaratives, as opposed to questions, results in
greater attitude change; employment of empty adjectives (“cute,” “sweet”)
degrades message acceptance as does being overly polite. The use of hedges (“I
guess,” “kinda,” “you know”) and intensives (“very” and other superlatives) tends
to hamper message acceptance, while use of powerful language (“it is,” and “no
doubt”) adds credibility (Burrell & Koper,1998).
Although historically audiences were thought to be passive, taking in
whatever message was brought to them, that conceptualization has changed. In
the past audiences were thought of as infused with information, much like a
person is injected with medicine by means of a hypodermic syringe. In more
recent years the theoretical position that audiences actively process information
has taken root (Perloff, 1993). It is said that listeners may do this in either of two
styles, systemic or heuristic, the latter also known as the elaboration likelihood
model—ELM (e.g., Booth-Butterfield, 2005; Petty & Cacioppo, 1986). When a
listener is responding systemically, he or she is actively involved, is alert, is
attending to details and is weighing the content that is being presented. In
contrast, when a listener is responding heuristically, he or she is more influenced
by superficial variables such as physical attractiveness and verbal style. Although
research continues along systemic/heuristic lines, it is clear from the host of
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variables described above, that the interplay of listener style, speaker style and
content is an area that has much to offer researchers in the field.
Where the biological causation model of mental disorders is concerned, any
effort to realign the attitudes and beliefs of mental health professionals with the
state of research would do well to give consideration to the antecedent variables
described above. Additionally, when one considers the training and experience of
front-line treating professionals, it is reasonable to assume that empirical data
would have significant impact in any presentation that is designed to change their
thinking. While heuristic factors should have some relevance for such an
audience, one would hypothesize that systemic factors, such as research data, may
well exert an even more powerful influence. That is because most mental health
practitioners (psychologists, counselors, clinical social workers, etc.) have
training histories in which research was emphasized, at least to some extent.
Heuristic factors and non-empirical cultural phenomena, such as ubiquitous
advertisements for medications, reach everyone including professionals.
Nevertheless, the role of empirical data in changing thinking ought to be
particularly important to practitioners whose training has placed emphasis upon
research. As well, the literature supports the notion that evidence enhances
changes in thinking (Perloff, 1993; Reinard, 1988).
It is possible, however, that evidence may be misperceived, or may not be
“evidence” at all. For example, when pseudo-scientific messages are employed,
particularly those that contain a great deal of scientific jargon, message
persuasiveness is enhanced (Haard, Slater, & Long, 2004). That may explain why
drug industry advertising is sufficiently persuasive that industry profits have
mushroomed. Nevertheless, it is clear that research evidence is an important
variable in the influence process. That should be particularly the case when the
audience is trained to appreciate and utilize research, although one would still
expect a professional audience to be influenced to some extent by heuristic
variables.
Audiences tend to pay greater attention when the speaker’s message has high
relevance for them. For example, when students listened to a presentation about
potential changes in comprehensive exams, the message had greater impact if the
proposed changes would affect their exams, as opposed to exams of some future
generation of students (Kerr, 2002). Similarity (e.g., age, sex) of presenter and
audience also affects change in attitude, and that factor is most powerful if a
similarity (e.g., profession) is relevant to the message presented (e.g., Perloff,
1993). Ultimately, it would seem, an audience of mental health practitioners
would be influenced by research evidence, as the credibility enhancing effects of
evidence seem consistent (O’Keefe, 1998; Reynolds & Reynolds, 2002).
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Several specific factors tend to cause a data-based message to be favorably
received. One factor appears to be the citation of sources (Fleshler, Ilardo, &
Demoretcky, 1974; O’Keefe, 1998). The failure to cite relevant sources may
result in changes in the opposite direction of that predicted by the speaker, and the
outcome may be even worse if no supporting citations are cited to counter an
opposing message that is supported (Reynolds & Reynolds, 2002). Thus, it is not
surprising that pharmaceutical industry advertising frequently cites “doctors” and
“researchers.”
Whether anecdotes help or harm a speaker’s efforts to bring about changed
thinking within the audience may depend on several factors. Some research
suggests that anecdotes may be as persuasive as statistical data when the audience
is only moderately involved (Baesler, 1997). Other data indicate the superiority of
data over anecdote (Allen & Preiss, 1997). Some research has suggested that
statistical evidence is better at producing desired knowledge in the listener, while
anecdotes result in greater affective change (Kopfman, Smith, Ah Yun, and
Hodges, 1998). In training professionals it probably is wise to employ both
statistical evidence and anecdote, with the preponderance going to statistical
evidence, in any effort to bring about attitude/belief change.
Whether the listener finds the evidence to be valid may also depend upon his
or her prior knowledge of the subject. Evidence is unlikely to have impact upon
an audience that lacks prior information about the topic (Reynolds & Reynolds,
2002). Perhaps that is because an audience must perceive the evidence as
legitimate, and it may be difficult for that to occur with a naïve audience. An
audience must be able to follow a link from evidence evaluation to overall
message evaluation, to a change in acceptance (Reynolds, 1986/1987).
Another factor known to influence a listener is the perception of bias in the
presentation. At least a few statements that are at odds with the speaker’s evident
bias tend to result in greater credibility of the speaker (e.g., McCroskey, 1969).
However, a speaker walks a fine line in that regard. Once a source is seen as
invalid on one bit if information, his or her credibility may be weakened on other
information (Schul & Mayo, 1999). Some research has shown that audience
members whose initial position is in agreement with the speaker prefer statistical
evidence, while those who oppose the position advanced by the speaker find
anecdotal stories to be more persuasive (Slater & Rouner, 1996).
A look at the audience reactions to U.S. presidential candidates engaged in
debates revealed that it is possible to present too much information. However, the
authors acknowledged that such candidates are probably already expected to have
a great deal of knowledge and to be quick to bring forth that knowledge.
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Candidates likely had more credibility to lose than to gain, a fact which may have
accounted for the effect in their study (Lavasseur & Dean, 1996).
Thus, the literature suggests that members of a relatively sophisticated
audience, such as professional mental health practitioners who are unlikely to
enroll in a full semester’s academic course, would be most amenable to a change
in their thinking during a brief training program under several specific conditions.
The speaker should present material in a relatively fluent manner, using a
“socially powerful” verbal style. The presentation should be primarily supported
by data, with citations, and should minimize use of anecdotes. The message must
be seen as highly relevant by the audience and some mention should be made of
information that goes against the presenter’s evident perspective. Finally, the
presenter is careful to avoid data overkill.
Selection of Training Program Content: Rise of the Biological Model
A brief training program could well employ the techniques described above
as it addresses issues of social importance. One such issue is the increasing
tendency toward biological conceptualizations of common disorders and
medications as the preferred treatment modality. Such training should be
important to all practitioners, but might resonate particularly well with nonmedical personnel. Of special interest is the extent to which non-medical
practitioners accept various facets of the biological model as valid, and whether
brief training would alter their thinking. Although it is not the purpose of this
article to thoroughly review the topic here, as that is a task that surely would
consume a number of articles, several of the more salient issues are presented
below.
The gap between what is known about biological causation of common
disorders and what is sometimes claimed may be illustrated by findings involving
the neurotransmitter serotonin. Although a connection between serotonin and
depression is frequently seen in pharmaceutical industry advertisements, such
claims are at odds with the opinions of experts in the study of serotonin and mood
(Lacasse & Leo, 2005). The absence of evidence caused Wayne Goodman, Chair
of the Psychopharmacologic Advisory Committee of the U.S. Food and Drug
Administration, to say that the chemical imbalance theory of depression is a
“useful metaphor” but one which should not be employed when doctors talk to
patients (Ross, 2008).
In contrast to the drug industry’s marketing claims of the era, in the late
1990s and early 2000s many academic sources continued to employ substantial
caution when the causes of common disorders were discussed, as several
representative examples make clear. Chapter two of an extensive report (U. S.

52

BIOLOGICAL CAUSATION?

Department of Health and Human Services, 1999) by then Surgeon General David
Satcher began, “The precise causes of mental disorders are not known” (p. 49).
Similarly, the Introductory Textbook of Psychiatry (Andreason & Black, 2001)
stated, “Much of the current investigative research in psychiatry is directed
toward the goal of identifying the pathophysiology and etiology of major mental
illnesses, but this goal has been achieved for only a few disorders…” (p. 23). The
Textbook of Clinical Psychiatry (Hales & Yodofsky, 2003) cautiously noted,
“Although reliable criteria have been constructed for many psychiatric disorders,
validation of the diagnostic categories as specific entities has not been
established” (p. 43). At odds with those careful statements, the medical director of
the American Psychiatric Association claimed publicly that the same three
sources had provided powerful evidence in support of biological causation for the
majority of disorders (MindFreedom, 2003).
A phenomenon driving the debate about causality is that the current treatment
of choice for many common disorders is medication. When treating professionals
and/or clients are convinced that the client’s difficulties in functioning are mostly,
or completely, biologically caused, they may be poorly motivated to undertake
non-drug interventions such as those based on a functional analysis of
environmental variables (Pelham, 2009; Stettin, Yao, Verbrugge, & Aubert,
2006). Skinner (1956) noted the difficulties that arise when behavior is viewed as
evidence of an underlying sickness: “It is rare to find behavior dealt with as a
subject matter in its own right. Instead, it is regarded as evidence for a mental life,
which is then taken as the primary object of inquiry” (p.84). Replace “mental life”
with “biological illness” and the contemporary status is relatively well described,
at least for many individuals.
The history of the U.S. culture’s turn to biological explanations is intriguing,
with several identified factors involved. Between 1970 and 1980 the percentage of
medical school graduates choosing psychiatry as a specialty had dropped by more
than half, from 11% to 5%. Organized psychiatry then undertook efforts to recruit
more medical school graduates into the field, and it did so, in part, by advocacy of
the precept that psychiatry would need to become more “biological,” and thus
more scientific, if it was to regain lost esteem and influence (Nelson, 1982).
Also around that time a turf war between psychiatry and what psychiatry saw
as “intruder” professions intensified psychiatry’s efforts to become more medical.
Clinical psychologists had initiated efforts to expand their scope of practice to
include hospital admission privileges (APA Practitioner Focus, 1990), the right to
be reimbursed by Medicare without supervision by a physician (Buie, 1989), and
prescription privileges (Seaman, 1997). The fields became embroiled in disputes
that at times generated visible hostility, and that have continued into the present
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century (Fox, 2002). A biological worldview tended to buttress psychiatry by
emphasizing its status as a medical profession.
The American Psychiatric Association’s response to a recent challenge is of
interest. The psychiatrists’ guild responded to a challenge by a group of
professionals and former patients who pressed the doctors’ group to provide
research evidence in support of biological causation of depression, anxiety and
other commonly diagnosed disorders. The psychiatric organization’s medical
director supplied references to various samples of academic literature that,
ironically, contained relatively weak empirical support for the organization’s
position, and instead made clear that the causes of most major disorders are
unknown. When that was pointed out, the psychiatric organization released a
position statement reasserting its faith in biological causation, but provided no
supportive evidence (MindFreedom, 2003).
It has become common to learn of research said to support biological
causation. However, much of this research has received insufficient critical
scrutiny. Family studies that seemed to validate genetic contributions, such as
studies of identical twins who were reared apart, have been plagued by
methodological and interpretation difficulties. For example, recent examination of
a table (Gottesman, 1991) that is commonly reproduced in textbooks and articles,
and which shows elevated risk for schizophrenia based on genetic relatedness, has
revealed that the table’s pooled results may be parsimoniously explained by
environmental factors (Joseph & Leo, 2006). Similarly, studies of brain structure
and functioning, as are done on autopsy or by employment of PET (Positron
Emission Tomography) and fMRI (functional Magnetic Resonance Imaging)
scans, have provided vivid images of brain functioning accompanied by
unwarranted conclusions that biological causes of disorders were on view.
The twin studies consistently find concordance rates above population
baselines for most disorders and, thus, have consistently been interpreted to
provide convincing evidence of at least partial genetic causation. However,
seldom have twin researchers accounted for the environmental variables that
might have brought about concordance rates for various disorders. For example,
even when identical twins are separated soon after birth and reared apart, their
environments’ responses to their identical levels of physical attractiveness and
ages at which they reach puberty are routinely ignored or downplayed in the
literature. Both attractiveness and rate of development, which are identical for
identical twins regardless of where they are raised, are known to be related to
emotional and behavioral status. Further, adoption agencies often require that
adoptive parents match the birth parents with regard to religion, socioeconomic
station and urban/rural status, variables that also are associated with emotional
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and behavioral development. Moreover, many sets of identical twins that were
said to have been reared apart were actually reared in the same extended family,
according to the twin researchers themselves. Thus, it is likely that identical twins
reared “apart” may well have been reared in environments that responded to them
quite similarly, and in ways known to influence behavioral status. Twin
researchers have usually failed to account for such factors (Joseph & Leo, 2006;
Midkiff & Wyatt, 2006; Wyatt, 1993; Wyatt, Posey, Welker, & Seamonds, 1984).
Similar to the issues that confound family and twin studies, research that
looks at brain structure and functioning via fMRI, PET scans and autopsy may
easily be misinterpreted. Often the findings are taken as evidence of causation
when they serve only as evidence of correlation. Although researchers typically
caution against making causal attributions, the vivid images of brain hot spots,
oversized ventricles and the like are frequently seen in pharmaceutical industry
advertising and are presented in ways that tend to reinforce the notion that brain
events are causal. While at times that may be accurate, as with brain tumors, in
most cases of depression, anxiety and other common disorders a causal
connection between unusual brain structure/function and the disorder is cannot be
shown.
Related to that, it would be quite surprising if, for example, an individual
who is experiencing depression had no identifiable changes in brain activity or
structure. A parsimonious explanation of depressive thoughts, feelings, overt
behaviors and brain changes may be that the individual has recently experienced
elevated stressful life circumstances. Alternatively, a person who has not
undergone such experiences may be depressed because he or she has never
learned adequate coping skills and is easily overwhelmed by routine levels of
stress (Wyatt, 2003; Wyatt, 2006). In either event, the brain’s structural and
functional changes in response to environmental events, termed neuroplasticity,
have long been documented yet typically de-emphasized in both drug
advertisements and research reports (Valenstein, 1998).
Non-empirical events have reinforced the biological model. Quite visible
among these are the financial interests and advertising practices of the
pharmaceutical industry. Although recent years have witnessed increasing sales of
psychotropic medications, a number of meta-analytic reviews have revealed that
evidence for effectiveness of some medications is relatively weak, a surprising
finding given the frequency with which medications are prescribed (Khan,
Leventhal, Khan, & Brown, 2002; Sommers-Flanagan & Sommers-Flanagan,
1996). A meta-analysis of 19 double-blind studies of top-selling antidepressants
showed that placebo effects accounted for approximately 75% of the patients’
improvement. Moreover, the authors asserted that the remaining 25%
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improvement could have been the result of an enhanced placebo response due to
the side effects that patients experience when taking an active drug, or other
factors (Kirsch & Saperstein, 1998; Kirsch & Weixel, 1988). Similarly, a review
of 29 published and 11 unpublished studies found that the anti-depressant Paxil
was better than placebo at improving symptoms of acute, moderate-to-severe
major depression, but that Paxil’s uncomfortable side effects caused such high
discontinuation rates that the drug overall is “…not better than placebo…”
(Lundberg, 2008).
Busy physicians who prescribe psychotropic medications may be unable to
keep current on such research. One study revealed that forty percent of primary
care physicians followed neither long-term medication follow-up guidelines nor
guidelines for patients who were non-responsive to the medications (Hepner,
Rowe, Rost, Hickey, Sherbourne, Ford, Meredith, & Rubenstein, 2007). Physicians are routinely targeted by drug makers’ representatives. Sales pitches and
perks to physicians have become so prevalent that a number of medical schools
have begun to train students in ways to resist them (Caruso, 2006). Many doctors
may routinely be misled and may then convey misinformation about causes of
disorders to their patients.
Related to the above, drug study methodology has come under greater
scrutiny in recent years. For example, methodological concerns regarding the
placebo run-in or “washout” phase have received increasing attention (Leutcher,
Cook, Witte, Morgan, & Abrams, 2002; Lydiard, Steiner, Burnham, & Gergel,
1998; Nierenberg et al., 1995; Londborg, Wolkow, Smith, DuBoff, England,
Ferguson, Rosenthal, & Weise, 1998; Pohl, Wolkow, & Clary, 1998; SommersFlanagan & Sommers-Flanagan, 1996). A placebo washout phase takes place
prior to the actual study. All potential subjects are given a one-to-three week
clinical trial of a placebo. Potential subjects who respond favorably to the placebo
are then excluded from further participation in the study. Then the remaining
individuals become the study’s subjects. They are divided into two groups (drug
v. placebo). Results that suggest a drug effect tend, thus, to be inflated due to the
intentional exclusion of many placebo responders from the subject pool. When
studies using the washout methodology, as most studies do, are presented to
professionals or the public, there is typically little attention to implications of the
washout phase (Wyatt, 2003).
Potential over-generalization of drug treatment effects from research
participants to the general population represents an additional thorny issue.
Research subjects usually must meet stringent exclusion and inclusion criteria
and, thus, are less than representative of the population of individuals with
specific disorders (Khan, Leventhal, Khan, & Brown, 2002). For example,
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patients are frequently excluded from studies of antidepressants if they: failed to
respond to any previously prescribed antidepressant during the current episode;
had another Axis I disorder; experienced any serious medical illness; presented
with significant lab tests (CBC, urea nitrogen, creatinine, electrolytes, plasma
glucose, liver function, thyroid, etc); were receiving anticoagulants; had a positive
drug screen; reported suicidal ideation; ever received CBT or ECT; were pregnant
or lactating; were women of childbearing potential who were not using
contraceptives or if they had responded to placebo during the 2-3 week washout
period (Nierenberg, McLean, Alpert, Worthington, Rosenbaum, & Fava, 1995;
Zimmerman, Chelminski, & Posternak, 2004). Such exclusions are important and
protective. However, they tend to limit generalization of the results.
At times, administrators of managed care programs have argued that
psychotherapy is "enhancement, not treatment" (Valenstein, 1998). That view
may be reflected in the fact that, until recent legislation, many health insurance
plans paid 80 percent of the physician fee, but only 50 percent of the nonphysician psychotherapist's usual fee. Several meta-analyses of studies involving
thousands of patients have compared medication to non-medical therapies and
have found that therapy is as effective as medication for treatment of depression
in the short term, and more effective than medicine in the long term (Jacobson &
Hollon, 1996; Hollon, 1996; Antonuccio, Danton, & DeNelsky, 1995). While
such findings enlighten non-medical therapists, the results have yet to generate
widespread enthusiasm among insurance providers who continue to push for
biological treatment of presumed biological disorders.
Financial incentives for the drug industry have contributed to the upswing in
use of psychotropic medicines over the past thirty years. Prescription of
psychotropics increased 20% from 1985 to 1994 in the United States. During
essentially the same period, prescriptions for stimulants tripled and those for
mood elevators doubled to 20 million (Pincus, Tamielian, Marcus, Olfson, Zarin,
& Thompson, 1998). In the widely read journal Pediatrics the number of fullpage advertisements for stimulants doubled from 1990 to 2000 (Wyatt, 2003). In
1996, the year that direct-to-consumer advertising of prescription medications was
legalized, U. S. patients spent $3.8 billion on anti-depressants. That had nearly
tripled to $9.9 billion by 2001 (Millenson & Shalowitz, 2005). Many drug
advertisements suggest, or specifically state, that mental and behavioral disorders
are “medical illnesses” similar to diabetes or other illnesses, and heavily imply
that drugs are the treatment of choice. Thus, the pharmaceutical industry’s
contributions to unwarranted perceptions of biological causation are well known
(Lacasse & Leo, 2005).
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Drug researchers’ conflicts of interest (that may have fueled reliance on
medications and, thus, acceptance of the biological model) gave rise to the
question, “Is academic medicine for sale?” It was asked by Marcia Angell, then
Editor-in-Chief of The New England Journal of Medicine. Her question was
prompted by the fact that many drug researchers have financial links to drug
companies, links numerous enough among the journal’s authors that Angell
reported she had insufficient space to list them all in the journal. Moreover,
Angell postulated that drug companies increasingly promote the creation of
“diseases” to fit their drugs, and that some among the populace are coming to
believe they suffer from serious ailments that, perhaps, do not exist (Angell,
2000). More recently the editor of the Journal of the American Medical
Association, Catherine DeAngelis, wrote that pharmaceutical companies have so
much influence that one would have to be “deaf, blind and dumb not to see it….”
She added that the medical community has “…allowed them to take over, and it’s
our fault…” (reported in Johnson, 2008). Given this state of affairs, it is difficult
to rule out the possibility that researchers’ conflicts of interest have played into
drug makers’ advocacy of the biological model.
At a glance, the randomized double-blind, placebo controlled studies such as
those published in the Journal of American Medical Association can appear quite
convincing, especially when it comes to data on drug efficacy. As one journal
editor put it, the quality of the journal will bless the quality of the drug (Smith,
2005). Most professionals trust the peer-reviewed journal as a reliable source of
information. Those such as Angell and DeAngelis have bluntly raised a concern
that medical journals are evolving into extensions of the marketing arms of
pharmaceutical companies (Smith, 2005). A review of eighty-five studies of
twelve anti-depressants found that 37 of 38 that produced positive results were
published, while only 3 of 36 with negative results were published and 11 with
negative or questionable results were written as if the drug had been effective
(Turner, Matthews, Linardatos, Tell, & Rosenthal, (2008).
Editors are required to meet budgeting demands, as well as provide scholarly
articles for professional consumption. Drug companies, except perhaps in rare
instances, do not attempt crude efforts to “fudge” data. Rather, the pharmaceutical
industry exerts subtle influence because it underwrites 75% of the studies
published in many of the major journals such as Annals of Internal Medicine,
Journal of the American Medical Association, Lancet, and New England Journal
of Medicine (Smith, 2005). It is reasonable to conclude that such practices can
create conflicts of interest (Brennan et al., 2006). There have been suggestions
that drug makers have promoted the over-diagnosis (and possible creation) of
disorders that their drugs will then treat. For example, in 1994 approximately
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20,000 U.S. children were diagnosed with bi-polar disorder. That had risen to
800,000 by 2003, and children’s prescriptions of anti-psychotic medications had
shown a corresponding increase (Olfson, Blanco, Liu, Moreno, & Laje, 2006).
The tendency for high-profile physicians to receive income from drug
companies and then promote those companies’ drugs had reached surprising
levels by the mid-to-late 2000s. A case in point is that of Dr. Frederick K.
Goodwin, who was host of PBS’s now-defunct “The Infinite Mind.” On his
September 20, 2005, radio show Goodwin promoted “…modern treatments—
mood stabilizers in particular—(that) have been proven both safe and effective in
bipolar children.” The same day, Goodwin was paid $2,500 by Glaxo-SmithKline for his promotional presentation for its mood stabilizer Lamictal.
Confronted with his evident conflict of interest, Goodwin responded, in part, “…it
didn’t occur to me that my doing what every other expert in the field does might
be considered a conflict of interest.” He added, “These (pharmaceutical)
companies compete with each other and cancel each other out.” Goodwin
received $329,000 that year from GSK for promoting Lamictal (Harris, 2008).
One additional variable that tends to reinforce, and is reinforced by,
medicalization of disorders is the layperson’s preference for the biological model.
Among the populace, many believe that a psychological explanation implies that a
person is weak or has not tried to overcome his problem (Link, Struening, Rahav,
Phelan, & Nuttbrock, 1997; Wahl, 1999). The preference among patients and
families for a non-stigmatizing, responsibility-shifting view of behavioral
disorders has been magnified by direct-to-consumer advertising. The downside is
that the causes of patients’ maladaptive behaviors may be overlooked, at least to
the extent that the causes are located within patients’ environmental and learning
histories.
The Present Study
The above discussion of the rise of the biological causation model served as
background for development of a three-hour training program for professionals.
The present study was an effort to make use of empirically derived training
strategies in a three-hour program for front-line mental health professionals
regarding two socially important, treatment-relevant phenomena—the surge of the
biological causation worldview of mental and behavioral disorders and efficacy of
drug treatment. This research was designed to explore whether such training
would change professionals’ views of these two phenomena as they relate to
common disorders such as depression, anxiety disorders and others. This is
important because it is likely that, for many professionals, such education is a pre-
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requisite to, although certainly not a guarantee of, corresponding changes in
clinical practice behaviors.
Method
Participants. Participants were 76 mental health professionals and
paraprofessionals ranging in age from 18 to 63 (see Table 1) who attended a
three-hour training program.
Ninety percent of the participants were identified as non-medical mental
health employees and all were recruited through announcements sent to agencies
to be posted, and a state psychological association membership flyer about the
training opportunity, including that continuing education credit was available.
Credit was not contingent upon pre-post completion of the assessment form.
The control group consisted of 26 graduate students in a doctoral training
program in clinical psychology who were enrolled in an advanced statistics class.
They ranged in age from their twenties to their fifties. Many possessed master’s
degrees and several had more than ten years of full-time clinical experience at the
master’s level. Participation was voluntary. The content of the class included no
components of the training program.
All subjects in both groups completed an informed consent in accordance
with the Ethical Principles of Psychologists and Code of Conduct - Principle 6.11.
Materials. The Strength of Belief Scale (SOBS) is a 38-item survey
containing six domains of interest to this research: A general biological causation
domain indicated overall acceptance of the biological causation model for a range
of mental health problems (anxiety, addiction, depression, ADHD, &
Schizophrenia). A layperson domain assessed professionals’ perceptions of
laypersons’ preference for biological explanations. An empirical domain
examined importance of research findings to professionals regarding causation of
mental disorders. The pharmaceutical domain looked at the professionals’
perceptions of pharmaceutical industry influence upon the rise of the biological
causation model. A guild domain measured attendees’ views of organized
psychiatry’s promulgation of biological causation. A health maintenance
organization (HMO) domain assessed attendees’ views of the insurance industry’s
preference for the biological model (See Table 2).
Each of the 38 items was rated on a Likert-type scale of one to six, with 1
indicating “strongly agree” and 6 indicating “strongly disagree”. The intervening
points on the Likert scale were agree (2); somewhat agree (3); somewhat disagree
(4) and disagree (5).
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Table 1. Participants
Frequency

Percent

Age:
18-26
27-35
36-44
45-53
54-62
63+
Total

2
14
8
25
20
7
76

2.6
18.4
10.5
32.9
26.3
9.2
100.0

Education:
High school
Associate degree
Bachelor’s degree
Master’s degree
Doctoral degree

2
2
13
31
28

2.6
2.6
17.1
40.8
36.8

Discipline:
Psychologist
Social Worker
Counselor
Other

45
11
12
8

59.2
14.5
15.8
10.5

Employment:
Community mental health
State hospital
Private practice
General hospital
For profit psychiatric hospital
University
Other

7
2
28
2
11
6
20

9.2
2.6
36.8
2.6
14.5
7.9
26.3
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Table 2. Strength of Belief Scale (SOBS) items. Participants responded to each
item on a scale from (1) strongly agree to (6) strongly disagree.
1. Attending pharmaceutical company sponsored workshops is helpful for me to
understand the benefits of psychotropic medication. (P)
2. Anxiety is a biological disorder. (B)
3. In studies of effectiveness of psychotropic drugs, the people who take the
experimental drugs are representative of the general population. (E)
4. Medication is less costly than psychotherapy in the eyes of Health Maintenance
Organizations (HMO) and other health insurance agencies. (H)
5. Doctors are experts. (L)
6. Most people in America think that a diagnosis of a mental disorder implies that a
person is weak. (L)
7. Family physicians acquire their practical knowledge about psychotropic
medication from the pharmaceutical company representatives. (P)
8. A mental illness believed to be biologically caused offers greater hope for
recovery than non-biologically caused mental illness. (L)
9. Health Maintenance organizations (HMO) and other health insurance agencies
limit coverage of the number of psychotherapy sessions much more so than the
number of office visits for medication refills. (H)
10. Social workers are well suited to diagnose and treat mental disorders. (G)
11. Financial interests of pharmaceutical companies have brought about unverified
claims of causation of mental disorders. (P)
12. Medical doctors are figures of authority. (G)
13. Unipolar depression is a biological disorder. (B)
14. Studies of identical twins who were separated soon after birth and reared apart
show fairly high levels of concordance for various mental and behavioral
disorders. (Concordance means if one twin develops a disorder such as
depression or schizophrenia later in life, then the other develops it too.) (E)
15. Studies have shown that people with psychological problems have more or less
of certain brain chemicals called neurotransmitters. (E)
16. Most people in America think that a diagnosis of a mental illness implies a
person has not tried to overcome his or her problem. (L)
17. Pharmaceutical company television advertisements for psychotropic medications
are believable. (P)
18. Health Maintenance Organizations (HMO) and other health insurance agencies
put the patient first. (H)
19. Medical doctors should be believed. (G)
20. Psychiatrists are well suited to diagnose and treat mental disorders. (G)
21. ADHD is a biological disorder. (B)
22. The majority of mental disorders are biological illnesses rather than the result of
poorly learned coping skills. (B)
23. Schizophrenia is a biological disorder. (B)
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24. Psychologists are well suited to diagnose and treat mental disorders. (G)
25. Most of my knowledge about psychotropic medication comes from
pharmaceutical company representatives. (P)
26. Studies of identical twins who were separated soon after birth and reared apart
that show fairly higher levels of concordance for various mental and behavioral
disorders provide strong evidence for biological causation of mental disorders.
(E)
27. Counselors are well suited to diagnose and treat mental disorders. (G)
28. Psychiatrists acquire a significant amount of their practical knowledge about
psychotropic medication from the pharmaceutical company representatives. (P)
29. Addiction is a biological disorder. (B)
30. It is important to listen to those of authority. (G)
31. There is evidence that biological abnormalities such as chemical imbalances,
brain lesions or genetic abnormalities cause most mental disorders. (E)
32. When depressed patients are given an antidepressant a large percentage of the
patients’ improvement is due to the placebo effect. (E)
33. Asking my doctor about medications advertised on television can be helpful in
finding the right medication that will meet my needs. (P)
34. If in the future scientists identify a specific gene that predisposes people to
become mentally ill, this would prove that mental illness is a disease. (E)
35. Studies that show people with psychological problems have more or less of
certain brain chemicals provide strong evidence for biological causation of
mental disorders. (E)
36. I trust that the medication prescribed to me by my doctor is what I need. (G)
37. If an expert said so, it must be true. (L)
38. The majority of mental disorders are biological illnesses rather than habit
disorders. (B)
Letters in parentheses indicate the domain to which the item belongs: (B)=Biological;
(L)=Layperson preference; (E)=Empirical; (P)=Pharmaceutical influence; (G)=Guild influence;
(H)=HMO.

The SOBS was developed in three steps. First, an initial set of items was
formulated based on intuitive judgment. They were submitted to members of a
university department of psychology faculty for feedback, which consisted mainly
of suggestions for editing along with intuitive perceptions of item relevance to the
study’s goals. After those adjustments were made, the revised surveys were
completed by a sample of advanced doctoral students. Items that correlated
weakly with other items within their specified domains were eliminated. A final
reliability analysis was conducted with the remaining thirty-eight items from the
treatment group data. Coefficient alphas ranged from .57 - .87 for the six
domains. (See Table 3.)
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Table 3. Reliability Analysis of Each Domain
Domain

α

Biological Domain

.73

Layperson Domain

.76

Empirical Domain

.77

Pharmaceutical Domain

.82

Guild Domain

.87

HMO Domain

.57

α = coefficient alpha

Design and procedure.
Educational Program. A 3-hr training program was developed. Following
much of the background information described above, it presented the historical
roots of the rise of the biological causation model and reviewed research often
cited in support of biological causation. Drug trial methodology and drug
effectiveness issues were presented, as well. The training was conducted in
didactic style by the second author who employed 90 power point slides (See
Table 4.)
It is of concern that the study’s second author also served as trainer. Several
procedures were installed to buffer possible presentation bias. At the outset the
presenter articulated a number of disorders that research has shown to have entire,
or very heavy, bases in biology. They included Down’s syndrome and disorders
due to tumor, endocrine dysfunction, known toxins, neurological damage
resulting from substance abuse and others. Additionally, the presenter stated that
an unknown percentage of cases of common disorders such as depression and
anxiety likely have biological roots. Further, the American Psychiatric
Association’s pro-biological point of view, as put forth in its response to the
MindFreedom (2003) challenge, was presented. Perhaps most important, the
program focused on research and encouraged attendee participation in discussion
of it. Finally, the presenter invited audience responses at any time during the
presentation. It is thought that possibility of biased presentation was minimized by
these procedures.
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Table 4. Outline, goals and objectives of the three-hour training program for
mental health professionals
Outline
•
•
•
•

•

•
•
•
•

Introduction and cautions: Some disorders are heavily biologically influenced.
Dilemmas in treatment.
When the patient’s conceptualization is biological, and wrong.
Non-empirical influences on patients’ and professionals’ thinking.
 Medical Guilds.
 HMO/Insurance Industry.
 Pharmaceutical companies.
 The patient’s worldview.
Critical thinking for the professional. What the research tells us.
 Genetic studies.
 Studies of brain structure and functioning.
 The disease model of addiction.
 ADHD: The food additive and sugar connections.
Putting our knowledge to use with patients.
Goals and Objectives
Attendees will explore the research on biological causation of abnormal
behavior.
Attendees will understand, and be able to articulate, the influences that lead
patients and professionals to adopt a biological causation worldview.
Attendees will be able to critically evaluate the research on genetic studies, twin
studies and studies of brain structure and function.

The treatment group participated in the training program. Prior to the
beginning of the training the participants were asked to complete the 38-item
SOBS. Upon completion of the training, participants were asked to again
complete the SOBS, which contained the same items as the pre-training form,
with the items randomly reordered.
A quasi-experimental non-equivalent groups design was utilized. Paired ttests (two-tailed) were used to test for pre-post changes within each group
separately. A linear regression analysis was conducted to evaluate whether a
change in perceptions regarding the domains (guild; pharmaceutical; layperson;
HMO/insurance; empirical) was associated with changes in belief in the
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biological causation domain, after controlling for the effect of several
demographic variables.
Results
Paired sample t-tests were conducted to evaluate whether participants showed
general change in reported strength of belief in biological causation of several
mental health disorders (ADHD, anxiety, depression, substance abuse, and
schizophrenia). The results indicated that, prior to the training, participants tended
toward agreement with the biological causation model of those disorders, and that
a post-training a shift toward disagreement had occurred (Mpre = 3.02, SD = .77)
(Mpost = 3.86, SD = .88), t (75) = 9.48, p = <.001. The standardized effect size
index, d, was 1.09, (See Table 5).
A paired sample t-test was also conducted to evaluate whether the training
changed the professionals’ opinions regarding the remaining four domains
(pharmaceutical, empirical, layperson, and guild). Mean ratings on the eight items
in the Empirical Domain were significantly changed from pre-training (Mpre =
3.29, SD = .74) to post-training (Mpost = 4.0, SD = .76), t (75) = 9.79, p = <.001.
Essentially, prior to training, participants felt that there was sufficient empirical
evidence to support a biological causation model for most common abnormal
behaviors but, post-training, there had been a shift toward disagreement.
There was also significant decline noted in the attendees’ faith in the claims
made by the pharmaceutical industry pre- (Mpre = 4.0, SD = .69) to postintervention (Mpost = 4.4, SD = .69), t (75) = 6.92, p = <.001. A modest increase in
skepticism regarding the psychiatric/medical guild’s claims of biological
causation resulted as well (Mpre = 3.1, SD = .69) (Mpost = 3.2, SD = .71), t (75) =
3.06, p = <.01.
A final set of paired sample t-tests was conducted to evaluate whether
participants in the control group showed any pre-post change. Results indicated
that no change occurred on any domain.
A standard multiple regression was performed between the pre-post
difference in strength of belief in the biological domain, as the dependent
variable, and the pre-post difference in strength of the pharmaceutical domain,
empirical domain, and guild domain as the independent variables. The HMO and
Layperson Domain were excluded from further evaluation, given that Pearson
correlations were found to be insignificant. Additional analysis included a
hierarchical regression in which the demographic variables of sex, age, and
education were controlled for prior to assessing the relationship between the prepost difference in strength of belief with the biological domain as the dependent
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Table 5. Pre and Post Training Means of Treatment Group
Domain

Mpre

Mpost

Mdiff

SDdiff

Biological Domain

3.02

3.86

-.83**

.8

Layperson Domain

3.4

3.5

-.1

.6

Empirical Domain

3.3

4.0

-.7**

.7

Pharmaceutical Domain

4.0

4.4

-.44**

.55

Guild Domain

3.1

3.2

-.2*

.5

HMO Domain

3.2

3.1

.2

.7

Mpre = pretest mean
Mpost = posttest mean
Mdiff = Mpre - Mpost
SDdiff = standard deviation of Mdiff
d = Cohen’s measure of effect size
*p < .01
**p < .001

variable and the pre-post differences in strength of belief with the pharmaceutical
domain, empirical domain, and guild domain as the independent variables.
Table 6 displays the results for the regression analyses. R for regression was
significantly different from zero: R2 = .340, F(3, 72) = 12.377, p < .001. The
combination of the three independent variables contributed significantly to
prediction of strength of belief in biological causation. Upon closer review of the
regression coefficients it seems that of the three variables, empirical domain had
the greatest influence. Age, sex, and education as predictors for strength of belief
in the biological domain were not significant, R2 = .053, F(3, 72) = 1.348, p =
.266. After controlling for these demographic variables, the three domains still
accounted for a significant proportion of variability ∆ R2 = .350, F(3, 69) = 13.49,
p < .001 .
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Table 6. Standard Multiple Regression of Guild, Empirical & Pharmaceutical
Influences on the Strength of Belief (SOB) in Biological Causation
Variables

SOB
BDMN
DV

G-INF

E-INF

G-INF

.355

E-INF

.530

.409

.395

.271

.380

.8302

.1702

.7319

P-INF
MEANS
STANDARD
DEVIATIONS

.76367

.48437

.65137

P-INF

B

β

.216

.137

.464**

.396

.288

.207

.4359
.54921

R2 =.340
Adjusted R2 =.313
R =.583**

*p < .01
**p < .001
SOB = Strength of Belief Scale
BDMN = Biological Domain
G-INF = Guild Influence
E-INF = Empirical Influence
P-INF = Pharmaceutical Influence
Numbers = Pearson Correlations

Discussion
This study examined whether a three-hour, data-based continuing education
training program that employed established antecedent methodology would altar
practicing mental health professionals’ perceptions of causation and drug
treatment. A three-hour time frame was chosen because practicing professionals
typically obtain continuing education by attending half-day training sessions and
are unlikely to enroll in full-semester graduate courses. The study looked at the
extent to which attendees, pre- and post-training, accepted a biological causation
worldview both generally and for several common disorders including ADHD,
unipolar depression, anxiety disorders, and schizophrenia.
The presentation employed several variables that the literature suggests are
most effective with a relatively sophisticated audience. The speaker was
reasonably well-known to the audience (university professor in a relatively small
state), well organized and presented the training fluently. He used data and cited
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sources. He was alert to the notion that data overkill can drain a presentation of its
impact. He avoided anecdote, although attendees occasionally described anecdotes about their clients.
The literature suggests that such an audience will respond favorably to some
evidence that goes against the general thrust of a presentation. Several facets of
the training were included to insure both that this was accomplished and, as
important, that the presentation was indeed balanced. For example, the presenter
stated that some disorders are caused biologically, and listed a number of them.
The training included the American Psychiatric Association’s defense of
biological causation, and other elements that were thought to serve as buffers
against bias. Representative research usually cited in support of biological
causation was examined. The historical roots of the ascendance of the model and
the dovetailing of interests of organized psychiatry and the pharmaceutical
industry and related topics, were presented.
The program’s critique of studies that are often cited as evidence of
biological causation, such as studies of identical twins reared apart and studies of
brain structure, function and chemistry, resonated particularly well with the
attendees, given the significant pre-to-post change in the empirical domain. That
finding is consistent with the systemic view (the listener is alert, responding to
facts) described above. This becomes particularly important when one considers
that the change occurred in experienced professionals, individuals whom one
might suppose had become somewhat inured against substantial world-view
changes. That the training was relatively brief adds to the importance of the
results because, unlike a full-semester graduate course which most practitioners
would be unlikely to pursue, professionals most often obtain continuing education
in half-day segments.
Exploration of the connection between the financial interests of the
pharmaceutical industry and the growth of the biological causation model,
although factually presented, may have reached attendees somewhat more
heuristically or emotionally. Participants came to the training with some degree of
conviction that the financial interests of drug companies have brought about
unverified claims of both causation and drug effectiveness. However, the brief
review of that topic strengthened attendees’ pre-existing skepticism.
It took minimal time to present methodological issues (the washout phase,
representativeness of study participants, power of the placebo) and interpretative
difficulties in studies of drug effectiveness. Nevertheless, that portion of the
training produced change in attendees’ thinking as well.
Thus, the study’s findings are consistent with the hypothesis that a brief,
research-based training program could alter the perceptions of active
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professionals regarding topics of importance in treatment settings—the causes and
treatment of common abnormal behaviors.
An issue in interpretation of the results is that our conceptualization of
causation as either “biological” or “not biological” leaves open the question of
contributions of both biology and environment, a perspective that no doubt
accounts for an unknown percentage of various disorders. However, it was the
intent of this research to discover whether the training would alter mental health
professionals’ worldviews. Thus, participants were required to choose something
other than a convenient mid-point.
Another concern arises when considering the presentation of data and
inferred change as a result of such presentation. It is difficult to extract the
influence of expert power (factual information provided by a skilled presenter)
from prestige or referent power (well known professor and likeable figure) when
inferring subjects’ responses to items (French & Raven, 1959, Aronson & Golden,
1962; Berlo, Lemest, & Martin, 1969; Haughtvedt, 1997). Therefore, left open to
some speculation is the question: Was it the message or the messenger that
brought about change? The answer is well beyond the scope of the present study.
However, it is important that it was the “package” of expert presenter, data,
source citations, historic review and the like that was effective. The conundrum is
that, with an esoteric topic and a professional audience, it is difficult to imagine a
credible presentation by an unknown individual with minimal, or no, credentials.
Another consideration lies in the measuring of change and what it means
to the individual professional. It is unknown how a unit of change in a
psychometric measure such as the SOBS might relate to a change, if any, in
practice (Blanton & Jaccard, 2006). We made no assumptions that changed
attitudes would be stable or that they would necessarily result in changes in
clinicians’ practices. Those are topics of future research. Rather, our assumption
is that the present study has established a platform on which changed practice
habits may be built. Without an enhanced, data-based change in thinking about
causation, it probably would be quite difficult to bring about changed techniques
in clinical practice.
A number of attendees informally remarked that the training had opened their
eyes to research issues that they had not considered and which had not been
addressed in their graduate training. Others pointed out that they had already felt
skepticism about claims of drug companies, but that the training helped them gain
focus on the specifics. Still others commented that the guild interests of organized
psychiatry were not new to them, but that they had been unaware of the extent to
which those interests had become symbiotic with drug industry interests.
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The informal comments were reflected in several items whose mean ratings
changed a full point, or nearly so, on the six-point SOBS scale. These included
items dealing with causes of several disorders (items 13, 21 and 23, Table 2) and
items dealing with the methodological and interpretive puzzles in research
looking at identical twins reared apart (items 14 and 26) and of brain chemistry
and structure (item 35). Critical examination of pharmaceutical industry influence
also was reflected in substantial change in the skeptical direction (item 1).
Aside from providing a training model, the program’s content suggests a
likely need for more public funding of trials, particularly of large head-to-head
trials of all treatments available for a given disorder. A federally regulated
website could house the studies. Journal editors might then concentrate on
critically describing the studies, instead of suffering the financial slings of staying
in publication (Smith, 2005).
The professional cultures would also do well to re-orient both themselves and
the populace as to what is, and is not, known about the causes of abnormal
behavior. Authors of textbooks, such as those that likely were read by the
professional participants in this study during their training, should revise their
books’ sections that deal with causation so that they offer in-depth, critical
analyses of data such as those presented in the present training program. Our
informal reviews of a number of frequently adopted textbooks revealed few that
approach that goal and none that, in our view, achieve it.
There are other content-related suggestions that arise from the three-hour
program’s results. Textbook authors and university professors would do well to
address cultural influences, such as direct-to-consumer advertising and
advertising to physicians. When a consumer responds to an ask-your-doctor
commercial, probability of prescription of that medication rises dramatically, even
when the patient presents with minor symptoms (Kravitz, Epstein, Feldman,
Franz, Rahman, Wilkes, Ladson, & Franks, 2005). The Food and Drug
Administration (FDA) would do well to move more forcefully to replace drug
company “education” with scientifically based information that will stimulate
better conversations between doctors and patients.
Physician education on several issues should be enhanced. For example,
physicians often cannot distinguish true statements from false ones when they
listen to sales pitches (Hopper, Speece, & Musial, 1990). Many physicians would
benefit from enhanced awareness of the impact of gifts, as the majority of them
feel that gifts given by pharmaceutical representatives do not influence their own
prescribing practices, but that such gifts do influence their colleagues (Steinman,
2000; Steinman, Shlipak, & McPhee, 2000).
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It is possible that improved government regulation of the claims made by the
drug industry, mass media organizations, and physicians’ groups may be of help,
although that task may well be very difficult. The Food and Drug administration’s
2007 Science Board report detailed difficulties with inadequate staffing, poor
retention of staff, out-of-date technology and a general lack of resources at the
FDA (FDA Science and Mission at Risk, 2007).
Undertaking a paradigm shift is a daunting task, given the financial resources
available to the pharmaceutical industry and to organized medicine. However,
given that a three-hour continuing education program, carefully employing
established antecedent teaching techniques, was able to bring about significant
change, large funding sources such as the National Institute of Mental Health may
yet be convinced to more vigorously support enhancement of empirically derived
understanding of mental health syndromes and treatment.
Although it was not this study’s purpose to resolve the debate about
etiological bases of behavior and treatment practices, this research provides a
basis for extension of the debate. This was an effort to determine whether the
thinking of professionals would be changed significantly as regards practice
related topics, within the confines of a brief continuing education program. That
goal was achieved. Such enhanced understanding would seem to be a prerequisite
if non-drug interventions such as applied behavior analysis are to flourish.
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